Agilent Technologies 2Q 2026: Revenue $1.84B, EPS $1.2— 10-Q Summary

Clinical OMICsReporter’s Notebook: Are One-Shot Gene Editors Ready to Tackle Chronic Illness?

Thermo FisherIndustry Roundup: Thermo Fisher Scales Orbitrap Platform Across Research, Biopharma, and Environmental Testing at ASMS 2026 - Chromatography Online

FierceBiotechASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas

AgilentAgilent Technologies 2Q 2026: Revenue $1.84B, EPS $1.2— 10-Q Summary - TradingView

FierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms

BioPharma DiveRallyBio tries again for reverse merger, this time with Avenzo

Endpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way

Endpoints NewsEpigenetic editing shows promise against chronic hep B infections

FierceBiotechASCO, Ryght AI team up for breast cancer trial site selection

Clinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs

Clinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side Effects

Endpoints NewsShionogi wins US approval for first pill to prevent Covid following exposure